Takigawa Masaki, Yatsu Tomofumi, Takino Yuka, Matsumoto Shigekiyo, Kitano Takaaki, Lee Jaewon, Arai Tomio, Tanaka Hiroyuki, Ishii Toshihiro, Mori Yoshiko, Ishigami Akihito
Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology.
Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital.
J Nutr Sci Vitaminol (Tokyo). 2019;65(5):399-404. doi: 10.3177/jnsv.65.399.
Vancomycin is recommended for treating severe infections caused by Gram-positive cocci, including methicillin-resistant Staphylococcus aureus. However, renal damage often occurs as a side effect because vancomycin is mainly excreted via the kidneys. The mechanism of vancomycin-associated nephrotoxicity is thought to involve the elevation of oxidative stress in the kidneys. Vitamin C (VC) has strong antioxidant properties; therefore, we evaluated the effect of high-dose VC preadministration on vancomycin-associated nephrotoxicity. Vancomycin was intraperitoneally injected into mice once daily for 7 d. Additionally, high-dose VC was intraperitoneally injected into mice at 30 min before vancomycin administration for 7 d. The plasma creatinine and urea nitrogen levels were increased by vancomycin treatment; however, high-dose VC preadministration suppressed the increase in these levels. Histological examination also revealed that high-dose VC preadministration reduced the characteristics of vancomycin-associated nephrotoxicity, such as dilated renal tubules with casts, the dilation of renal proximal tubules, and tubular epithelial desquamation. Furthermore, high-dose VC preadministration reduced the appearance of apoptotic cells presumably derived from the epithelial cells in the dilated proximal tubules. Thus, intraperitoneally injected high-dose VC preadministration reduced vancomycin-associated nephrotoxicity in mice. These novel findings may indicate that vancomycin-associated nephrotoxicity in humans may be reduced by high-dose VC preadministration.
万古霉素推荐用于治疗由革兰氏阳性球菌引起的严重感染,包括耐甲氧西林金黄色葡萄球菌感染。然而,由于万古霉素主要通过肾脏排泄,肾损伤常作为副作用发生。万古霉素相关性肾毒性的机制被认为与肾脏氧化应激升高有关。维生素C(VC)具有强大的抗氧化特性;因此,我们评估了高剂量VC预处理对万古霉素相关性肾毒性的影响。将万古霉素每天一次腹腔注射到小鼠体内,持续7天。此外,在万古霉素给药前30分钟将高剂量VC腹腔注射到小鼠体内,持续7天。万古霉素治疗使血浆肌酐和尿素氮水平升高;然而,高剂量VC预处理抑制了这些水平的升高。组织学检查还显示,高剂量VC预处理减轻了万古霉素相关性肾毒性的特征,如肾小管扩张伴管型、肾近端小管扩张和肾小管上皮细胞脱落。此外,高剂量VC预处理减少了可能源自扩张近端小管上皮细胞的凋亡细胞的出现。因此,腹腔注射高剂量VC预处理可减轻小鼠万古霉素相关性肾毒性。这些新发现可能表明,高剂量VC预处理可能降低人类万古霉素相关性肾毒性。